.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Baxter
UBS
Fish and Richardson
Colorcon
US Department of Justice
Cantor Fitzgerald
Novartis
Deloitte
Julphar

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,888,027

« Back to Dashboard

Which drugs does patent 6,888,027 protect, and when does it expire?


Patent 6,888,027 protects BELEODAQ and is included in one NDA.

This patent has sixteen patent family members in eleven countries.

Summary for Patent: 6,888,027

Title: Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Abstract:This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q.sup.1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: --S(.dbd.O).sub.2 NR.sup.1 -- and --NR.sup.1 S(.dbd.O).sub.2 --; R1 is a sulfonamido substituent; and, Q.sup.2 is an acid leader group; with the proviso that if J is --S(.dbd.O).sub.2 NR.sup.1 --, then Q.sup.1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis. ##STR1##
Inventor(s): Watkins; Clare J (Abingdon, GB), Romero-Martin; Maria Rosario (Didcot, GB), Moore; Kathryn G (Abingdon, GB), Ritchie; James (Abingdon, GB), Finn; Paul W (Abingdon, GB), Kalvinsh; Ivars (Riga, LV), Loza; Einars (Riga, LV), Dikovska; Klara (Riga, LV), Gailite; Vija (Riga, LV), Vorona; Maxim (Riga, LV), Piskunova; Irina (Riga, LV), Starchenkov; Igor (Riga, LV), Andrianov; Victor (Riga, LV), Harris; C. John (Sittingbourne, GB), Duffy; James E. S. (Sittingbourne, GB)
Assignee: Topotarget UK Limited (Abingdon, GB)
Application Number:10/381,790
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Spectrum Pharms
BELEODAQ
belinostat
POWDER;IV (INFUSION)206256-001Jul 3, 2014RXYesYes6,888,027► SubscribeYY TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,888,027

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0023986Sep 29, 2000
PCT Information
PCT FiledSeptember 27, 2001PCT Application Number:PCT/GB01/04326
PCT Publication Date:April 18, 2002PCT Publication Number: WO02/30879

Non-Orange Book Patents for Patent: 6,888,027

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,183,298Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors► Subscribe
7,557,140Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors► Subscribe
7,407,988Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,888,027

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand525439► Subscribe
New Zealand535065► Subscribe
Portugal1328510► Subscribe
Japan2009051845► Subscribe
Japan4975941► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Merck
Chinese Patent Office
Cerilliant
Chubb
Dow
Moodys
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot